MEDXZ Stock Overview
Designs, produces, and sells high-precision devices and services for the healthcare, consumer, and industrial end markets worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
medmix AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 10.34 |
| 52 Week High | CHF 23.10 |
| 52 Week Low | CHF 9.25 |
| Beta | 0.79 |
| 11 Month Change | 2.78% |
| 3 Month Change | -27.49% |
| 1 Year Change | -52.57% |
| 33 Year Change | -74.82% |
| 5 Year Change | n/a |
| Change since IPO | -74.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDXZ | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -0.3% |
| 1Y | -52.6% | 10.1% | 9.8% |
Return vs Industry: MEDXZ underperformed the UK Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: MEDXZ underperformed the UK Market which returned 9.8% over the past year.
Price Volatility
| MEDXZ volatility | |
|---|---|
| MEDXZ Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: MEDXZ has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: MEDXZ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1922 | 2,695 | Girts Cimermans | www.medmix.swiss |
medmix AG designs, produces, and sells high-precision devices and services for the healthcare, consumer, and industrial end markets worldwide. The company operates through Dental, Drug Delivery, Surgery, Industry, and Beauty segments. The company offers dental products, including mixing tips, dispensers, needles, accessories, and service solutions for various applications, such as prosthetics, adhesives, restoratives, prevention, esthetics and endodontics; drug delivery devices that are used to inject fertility drugs and growth hormones; and to treat niche diabetes indications, osteoporosis, and rare diseases; and mixing and delivery devices which are used to inject bone tissue, and to apply hemostatic sealants for internal and external wound treatment during surgical procedures.
medmix AG Fundamentals Summary
| MEDXZ fundamental statistics | |
|---|---|
| Market cap | CHF 424.20m |
| Earnings (TTM) | -CHF 1.80m |
| Revenue (TTM) | CHF 479.70m |
0.9x
P/S Ratio-235.7x
P/E RatioIs MEDXZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDXZ income statement (TTM) | |
|---|---|
| Revenue | CHF 479.70m |
| Cost of Revenue | CHF 323.40m |
| Gross Profit | CHF 156.30m |
| Other Expenses | CHF 158.10m |
| Earnings | -CHF 1.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 32.58% |
| Net Profit Margin | -0.38% |
| Debt/Equity Ratio | 62.4% |
How did MEDXZ perform over the long term?
See historical performance and comparison